

The 2026 meningococcal serogroup B cluster in the United Kingdom: a case for strategic reform

ARTICLE INFO

Keywords:

Invasive meningococcal disease
Serogroup B meningococcal disease
Adolescent vaccination
Outbreak surveillance and response

ABSTRACT

Invasive meningococcal disease (IMD) is re-emerging in the United Kingdom following suppression during the COVID-19 pandemic. In early 2026, an atypical outbreak of meningococcal serogroup B (MenB) disease occurred among adolescents and young adults in Kent, representing the most significant meningococcal incident in England in recent years. The outbreak was linked to intense social mixing in nightlife and university settings, resulting in multiple confirmed cases and fatalities, cross-border exposure, and extensive public health intervention including mass chemoprophylaxis and targeted vaccination. Despite the UK's comparatively strong meningococcal immunisation programme, the outbreak highlighted persistent vulnerabilities: waning infant MenB protection by adolescence, suboptimal MenACWY uptake in school-aged cohorts, delays in notification, and outbreak response systems poorly adapted to highly mobile student populations. Surveillance data indicate IMD has returned to near pre-pandemic levels, driven predominantly by MenB, while serogroups covered by adolescent MenACWY vaccination remain suppressed. This outbreak underscores the need to re-evaluate adolescent MenB vaccination policy, strengthen catch-up vaccination delivery, modernise outbreak communication and surveillance systems, and anticipate equitable access to vaccines during periods of heightened demand. Without strategic reform, similar outbreaks are likely to recur as IMD incidence rises.

Dear Editor,

Globally, calls for broader meningococcal serogroup B (MenB) immunisation continue, given its potential to reduce invasive meningococcal disease across multiple serogroups (Borrow et al., 2025). This context is particularly relevant to the atypical 2026 MenB outbreak centred in Kent, the most consequential meningococcal incident England has faced in recent years. Despite rapid chemoprophylaxis and targeted vaccination, the outbreak exposed structural weaknesses in adolescent and young-adult protection. As invasive meningococcal disease (IMD) returns toward pre-pandemic levels, this event underscores the need for a more assertive vaccination strategy, stronger routine coverage, and modernised outbreak response systems capable of matching the mobility and social behaviour of contemporary student populations.

A shifting epidemiological baseline

The Kent cluster emerged rapidly, with multiple confirmed MenB cases and two deaths, linked to a single high-density night club setting in Canterbury between 5 and 7 March. Known cases visited the venue during this period in which an estimated 4800 people attended ('Something I've never felt since Covid, 2026). The University of Kent is a second exposure site. Furthermore, France has reported a case of IMD in an individual potentially linked to the Kent outbreak (Very low risk for the EU/EEA, 2026). Public health authorities swiftly followed up with students and staff, issued daily updates, deployed ciprofloxacin prophylaxis and targeted MenB vaccination for several thousand students and staff (Notified cases of invasive meningococcal disease, 2026; NHS England, 2026). This was not a sporadic anomaly but an active and

expanding incident. As of 24 March 2026, UK Health Security Agency (UKHSA) has reported 20 confirmed and 2 probable cases of IMD linked to Canterbury, Kent. All confirmed cases are MenB, and 17 involve the outbreak strain subtype P1.12-1,16-183 (Notified cases of invasive meningococcal disease, 2026). Over 9800 antibiotic courses and 2,360 vaccines have been provided to eligible people in Kent ('Something I've never felt since Covid, 2026) (Fig. 1). In the United Kingdom (UK), meningitis is notifiable on clinical suspicion—lab confirmation isn't needed. Public health should be informed as soon as meningitis is suspected, although this is often overlooked. With the Kent cluster, there was an early delay in notification. The first suspected meningitis case was not reported to UKHSA till around 26 h after meningitis was suspected, breaching the requirement for immediate notification (MenB, 2026).

In April 2026, UKHSA confirmed a limited outbreak of MenB disease among adolescents and young adults in Weymouth, Dorset (Wise, 2026). Three epidemiologically linked cases were identified over a one-month period, all caused by the same MenB strain, distinct from that associated with the contemporaneous Kent outbreak. All cases recovered following prompt treatment (Wise, 2026).

Two vaccines protect against meningococcal meningitis: a three-dose MenB regimen for infants (at 8, 16, and 52 weeks) and MenACWY for adolescents in Year 9. MenB coverage at 12 months is 91.4% (2024–25 UKHSA data) (Invasive meningococcal disease in England, 2024), while MenACWY uptake in 2023/24 Year 9 students (ages 13–14) is 72.1% (Vaccination crucial as meningitis cases increase, 2026). National surveillance shows invasive meningococcal disease rising post-COVID to pre-pandemic levels, driven mainly by MenB, while serogroups targeted by the adolescent MenACWY programme remain suppressed through herd immunity (Meningococcal, 2024; Guidance for public health

<https://doi.org/10.1016/j.clinpr.2026.100637>

Received 19 April 2026; Received in revised form 29 April 2026; Accepted 4 May 2026

Available online 9 May 2026

2590-1702/© 2026 The Author(s). Published by Elsevier Ltd on behalf of British Infection Association. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Fig. 1. A profile of the 2026 Meningococcal serogroup B cluster in the United Kingdom.

management; Carr et al., 2020).

The UK has one of the most proactive MenB vaccination policies globally. The MenB vaccine was introduced into the UK routine childhood immunisation programme on 1 September 2015. As of 2025–26, only a minority of European countries include routine infant MenB vaccination in their national programmes (e.g. Ireland, Italy, Portugal, Lithuania, Malta, Czech Republic), while many others limit MenB vaccination to risk-based or outbreak settings rather than universal use (What are the recommended meningococcal vaccination schedules, 2026). Like the UK, no European country has yet adopted routine universal adolescent MenB vaccination, although several (notably Ireland and Italy) combine infant MenB programmes with adolescent MenACWY, giving broader life-course protection than most countries (What are the recommended meningococcal vaccination schedules, 2026).

Why the outbreak took hold

The Kent outbreak reflects a predictable convergence of risk factors: High meningococcal carriage in adolescents, enabling rapid spread during very close-contact events, with the possibility of exchange of saliva (Guidance for public health management); Intense social mixing, particularly in nightlife settings (Notified cases of invasive meningococcal disease, 2026). The concurrent surge in demand for private MenB vaccination and temporary supply constraints demonstrates how quickly public demand shifts when routine protection is perceived to be insufficient (Gil, 2026).

Policy lessons that cannot be deferred

MenB protection for older adolescents requires strategic reconsideration

The targeted MenB vaccination programme at the University of Kent was necessary, but it revealed a structural vulnerability, adolescents and young adults entering high-density social environments remain largely unprotected against MenB (Notified cases of invasive meningococcal disease, 2026; NHS England, 2026). Evidence supports the effectiveness of infant MenB vaccination and the strong indirect protection generated by adolescent MenACWY programmes (Guidance for public health management; Meningococcal, 2026). Infant MenB protection wanes by adolescence, so a new cost-effectiveness review of vaccinating older adolescents and new university entrants is needed. Although the Joint

Committee on Vaccination and Immunisation (JCVI) previously ruled this not cost-effective, the scale of the Kent outbreak and falling coverage justify revisiting that decision. The UK meningitis vaccine strategy is under active review by the JCVI.

Routine vaccination gaps must be closed with urgency

MenACWY uptake in school years 9–10 remains below pre-pandemic levels (Meningococcal, 2024), leaving incoming university cohorts unnecessarily susceptible. Closing gaps for those who missed MenB in infancy or MenACWY in years 9–10 requires stronger catch-up delivery across schools, colleges, and primary care, supported by digital recall systems that quickly identify and invite unvaccinated students. Mop-up vaccination can be used to target specific populations to eliminate IMD during outbreaks.

University-level demand will require expanded capacity through mobile units, pop-up clinics, extended hours, and rapid digital booking, with procurement planning that anticipates surges to ensure equitable access and avoid recent supply constraints (Gil, 2026).

Embed vaccines and antibiotics earlier in outbreak response

Ciprofloxacin prophylaxis was deployed rapidly in Kent, but vaccination lagged (Notified cases of invasive meningococcal disease, 2026; NHS England, 2026). Outbreak protocols should include pre-authorised triggers for rapid MenB vaccination to minimise delays between case confirmation and immunisation. Because MenB vaccination does not eliminate carriage, combined antibiotic and vaccination strategies remain essential (Outbreak of invasive meningococcal disease, 2026).

Communication systems must reflect modern mobility dynamics

Human mobility is now recognised as a key driver of epidemic transmission patterns, especially in settings like universities where populations disperse rapidly (Lu et al.). Students are highly transient, particularly during term breaks, making timely outreach difficult. Traditional channels, such as university email, are too slow for the pace of meningococcal transmission. Outbreak communication must instead leverage real-time, hyperlocal messaging such as SMS, app-based alerts, and social media to deliver clear, geo-targeted information on symptoms, prophylaxis, and vaccination sites, regardless of where students

are located (Lu et al.).

Surveillance must follow individuals, not administrative boundaries

Student mobility makes timely prophylaxis and vaccination difficult, especially when exposed individuals disperse before public health teams can trace or reach them (Notified cases of invasive meningococcal disease, 2026; NHS England, 2026). Current IMD surveillance relies on local notifications and postcode-based tracing, which do not reflect how students live, travel, or socialise. A modernised system is needed: national, real-time data integration particularly mobile phone and e-mail contact details to rapidly identify and notify at-risk individuals wherever they are, not just where an outbreak begins.

Equity must be protected during periods of heightened demand

The rush for private MenB vaccination during the Kent outbreak highlights potential inequities (Gil, 2026). Public vaccination programmes must anticipate demand spikes and ensure consistent access for students across diverse educational settings and socioeconomic backgrounds.

The Kent cluster highlights how meningococcal disease exploits gaps in surveillance, vaccine coverage, communication, and outbreak preparedness. With IMD nearing pre-pandemic levels, the UK cannot rely on reactive measures or past successes. Vaccine coverage must improve, adolescent MenB protection reconsidered, and outbreak systems upgraded for rapid vaccination and real-time communication (Fig. 1).

This should be a national turning point: without strengthened vaccination strategy and agile outbreak infrastructure, similar clusters will recur; with them, future outbreaks can be contained sooner or prevented entirely.

Funding

No funding was obtained for this work.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The views expressed in this Letter are those of the authors and do not reflect the views of the UK Health Security Agency or the British Infection Association.

References

'Something I've never felt since Covid. It was scarier': the shock and pain of Kent's meningitis outbreak | Kent | The Guardian. Accessed March 22, 2026. https://www.theguardian.com/uk-news/ng-interactive/2026/mar/21/how-meningitis-broke-out-kent-university-nightclub?CMP=share_btn_url.

- Borrow, R., Caugant, D.A., Clark, S.A., et al., 2025. Current global trends in meningococcal disease control, risk groups and vaccination: consensus of the Global Meningococcal Initiative. *J. Infect.* 91 (5), 106635. <https://doi.org/10.1016/j.jinf.2025.106635>.
- Carr, J., Plested, E., Aley, P., et al., 2020. 'Be on the TEAM' Study (Teenagers against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. *BMJ Open* 10 (10), e037358. <https://doi.org/10.1136/bmjopen-2020-037358>.
- Gil, E., 2026. Meningitis B in Kent: an outbreak in the shadow of a pandemic. *BMJ* 392, s547. <https://doi.org/10.1136/bmj.s547>.
- Guidance for public health management of meningococcal disease in the UK.
- Invasive meningococcal disease in England: annual laboratory-confirmed reports for epidemiological year 2024 to 2025 - GOV.UK. Accessed March 21, 2026. <https://www.gov.uk/government/publications/meningococcal-disease-laboratory-confirmed-cases-in-england-2024-to-2025/invasive-meningococcal-disease-in-england-a-annual-laboratory-confirmed-reports-for-epidemiological-year-2024-to-2025>.
- Lu X, Feng J, Lai S, et al. Human Mobility in Epidemic Modeling.
- MenB, W.J., 2026. Kent hospital admits "indefensible" delay in raising alarm about suspected meningitis case. *BMJ* 392. <https://doi.org/10.1136/BMJ.S581>.
- Meningococcal ACWY (MenACWY) vaccine coverage for adolescents in England, academic year 2024 to 2025 - GOV.UK. Accessed March 20, 2026. <https://www.gov.uk/government/publications/meningococcal-acwy-immunisation-programme-vaccine-coverage-estimates/meningococcal-acwy-menacwy-vaccine-coverage-for-adolescents-in-england-academic-year-2024-to-2025>.
- Meningococcal ACWY immunisation programme: vaccine coverage estimates - GOV.UK. Accessed March 20, 2026. <https://www.gov.uk/government/publications/meningococcal-acwy-immunisation-programme-vaccine-coverage-estimates>.
- NHS England » Outbreak of meningococcal disease linked to University of Kent and the area of Canterbury. Accessed March 20, 2026. <https://www.england.nhs.uk/long-read/outbreak-of-meningococcal-disease-linked-to-university-of-kent-and-the-area-of-canterbury/>.
- Notified cases of invasive meningococcal disease - GOV.UK. Accessed March 25, 2026. <https://www.gov.uk/government/publications/invasive-meningococcal-disease-statistical-releases/notified-cases-of-invasive-meningococcal-disease>.
- Notified cases of invasive meningococcal disease - GOV.UK. Accessed March 20, 2026. <https://www.gov.uk/government/publications/invasive-meningococcal-disease-statistical-releases/notified-cases-of-invasive-meningococcal-disease>.
- Outbreak of invasive meningococcal disease, South East England - GOV.UK. Accessed March 21, 2026. <https://www.gov.uk/guidance/outbreak-of-invasive-meningococcal-disease-south-east-england>.
- Vaccination crucial as meningitis cases increase - GOV.UK. Accessed March 21, 2026. <https://www.gov.uk/government/news/vaccination-crucial-as-meningitis-cases-increase>.
- Very low risk for the EU/EEA from the outbreak of invasive meningococcal disease in Kent, England. Accessed March 21, 2026. <https://www.ecdc.europa.eu/en/news-events/very-low-risk-eueea-outbreak-invasive-meningococcal-disease-kent-england>.
- What are the recommended meningococcal vaccination schedules (MenACWY and MenB) for infants, children, adolescents, and high-risk individuals in continental Europe? Accessed April 29, 2026. <https://www.droracle.ai/articles/920122/what-are-the-recommended-meningococcal-vaccination-schedules-menacwy-and-menb>.
- Wise, J., 2026. New meningitis B outbreak: three cases in Dorset are not linked to recent Kent wave. *BMJ* 393, s746. <https://doi.org/10.1136/BMJ.S746>.

Akaninyene Otu^{a,b,*} , Bassey Ebenso^a, Muiz Akinyemi^a, John Walley^a
^a Nuffield Centre for International Health and Development, University of Leeds, Leeds, United Kingdom
^b Mid Yorkshire Teaching Hospital NHS Trust, Wakefield, United Kingdom

* Corresponding author at: Nuffield Centre for International Health and Development, University of Leeds, Leeds LS2 9JT, United Kingdom.
 E-mail address: a.a.otu@leeds.ac.uk (A. Otu).